Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Roche AG’s Genentech unit disclosed outcomes of two studies testing IL-33-targeting astegolimab vs. placebo on top of standard-of-care maintenance therapy in subjects with moderate to very severe ...

The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of studies testing the compound vs. placebo on ...

Between baseline and week 16, patients in the astegolimab group experienced an adjusted mean percent change of –51.47% (95% CI, –68.75 to –34.19) in their Eczema Area and Severity Index ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Swiss pharma giant Roche today reported mixed results from late-stage trials for its experimental drug astegolimab, which is ...